- Home
- TJX vs GILD Comparison
TJX vs GILD Comparison
Compare TJX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TJX
- GILD
- Stock Information
- Founded
- TJX 1962
- GILD 1987
- Country
- TJX United States
- GILD United States
- Employees
- TJX 349000
- GILD N/A
- Industry
- TJX Clothing/Shoe/Accessory Stores
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TJX Consumer Discretionary
- GILD Health Care
- Exchange
- TJX Nasdaq
- GILD Nasdaq
- Market Cap
- TJX 137.0B
- GILD 113.0B
- IPO Year
- TJX N/A
- GILD 1992
- Fundamental
- Price
- TJX $121.86
- GILD $91.84
- Analyst Decision
- TJX Strong Buy
- GILD Buy
- Analyst Count
- TJX 19
- GILD 26
- Target Price
- TJX $129.89
- GILD $98.17
- AVG Volume (30 Days)
- TJX 4.8M
- GILD 6.6M
- Earning Date
- TJX 02-26-2025
- GILD 02-11-2025
- Dividend Yield
- TJX 1.23%
- GILD 3.35%
- EPS Growth
- TJX 19.82
- GILD N/A
- EPS
- TJX 4.24
- GILD 0.10
- Revenue
- TJX $56,421,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- TJX $4.75
- GILD $6.50
- Revenue Next Year
- TJX $5.70
- GILD $0.36
- P/E Ratio
- TJX $28.72
- GILD $908.39
- Revenue Growth
- TJX 7.83
- GILD 3.31
- 52 Week Low
- TJX $92.35
- GILD $62.07
- 52 Week High
- TJX $128.00
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- TJX 51.56
- GILD 51.58
- Support Level
- TJX $118.47
- GILD $90.82
- Resistance Level
- TJX $120.60
- GILD $93.07
- Average True Range (ATR)
- TJX 1.85
- GILD 1.54
- MACD
- TJX -0.07
- GILD -0.03
- Stochastic Oscillator
- TJX 57.79
- GILD 56.28
About TJX TJX Companies Inc. (The)
TJX Companies is the leading off-price retailer of apparel, accessories, and home merchandise in the United States. The firm leverages its more than 20,000 global vendor relationships to procure and sell brand-name merchandise at prices 20%-60% cheaper than conventional retail channels. TJX opportunistically purchases excess inventory that stems from manufacturing overruns and retail closeout sales. The off-price retailer disperses its vast and disparate merchandise across its 5,000 global stores, creating a treasure-hunt shopping experience for consumers. Over three quarters of TJX's sales are derived from the United States, primarily via the T.J. Maxx, Marshalls, and HomeGoods banners. About 10% of sales are from Canada and 12% from Europe and Australia.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).